CS272766B2 - Method of tertiary hydroxyalkylxanthine production - Google Patents

Method of tertiary hydroxyalkylxanthine production Download PDF

Info

Publication number
CS272766B2
CS272766B2 CS545386A CS545386A CS272766B2 CS 272766 B2 CS272766 B2 CS 272766B2 CS 545386 A CS545386 A CS 545386A CS 545386 A CS545386 A CS 545386A CS 272766 B2 CS272766 B2 CS 272766B2
Authority
CS
Czechoslovakia
Prior art keywords
group
formula
compounds
hydroxy
mol
Prior art date
Application number
CS545386A
Other languages
Czech (cs)
English (en)
Other versions
CS545386A2 (en
Inventor
Ulrich Dr Gebert
Ismahan Dr Okyayuz-Baklouti
Werner Dr Thorwart
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Priority to CS200789A priority Critical patent/CS272799B2/cs
Priority to CS200889A priority patent/CS272800B2/cs
Priority to CS200689A priority patent/CS272798B2/cs
Publication of CS545386A2 publication Critical patent/CS545386A2/cs
Publication of CS272766B2 publication Critical patent/CS272766B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CS545386A 1985-07-19 1986-07-17 Method of tertiary hydroxyalkylxanthine production CS272766B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CS200789A CS272799B2 (en) 1985-07-19 1989-03-31 Method of teriary hydroxylxanthine production
CS200889A CS272800B2 (en) 1985-07-19 1989-03-31 Method of tertiary hydroxyalkylxantine production
CS200689A CS272798B2 (en) 1985-07-19 1989-03-31 Method of tertiaryhydroxyalkylanthine production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853525801 DE3525801A1 (de) 1985-07-19 1985-07-19 Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung

Publications (2)

Publication Number Publication Date
CS545386A2 CS545386A2 (en) 1990-04-11
CS272766B2 true CS272766B2 (en) 1991-02-12

Family

ID=6276182

Family Applications (1)

Application Number Title Priority Date Filing Date
CS545386A CS272766B2 (en) 1985-07-19 1986-07-17 Method of tertiary hydroxyalkylxanthine production

Country Status (33)

Country Link
US (1) US4833146A (da)
EP (1) EP0268585B1 (da)
JP (1) JPH0788382B2 (da)
KR (1) KR950001019B1 (da)
CN (1) CN1026112C (da)
AR (1) AR244689A1 (da)
AT (1) ATE53211T1 (da)
AU (1) AU588350B2 (da)
BG (1) BG60767B2 (da)
CA (1) CA1262248A (da)
CS (1) CS272766B2 (da)
DD (1) DD261156A5 (da)
DE (2) DE3525801A1 (da)
DK (1) DK157867C (da)
ES (1) ES2001019A6 (da)
FI (1) FI89921C (da)
GR (1) GR861866B (da)
HU (1) HU198486B (da)
IE (1) IE59025B1 (da)
IL (1) IL79457A0 (da)
LT (1) LT3869B (da)
LV (1) LV5703A3 (da)
MA (1) MA20739A1 (da)
MX (1) MX9254A (da)
NO (1) NO165803C (da)
NZ (1) NZ216888A (da)
OA (1) OA08707A (da)
PH (1) PH26262A (da)
PT (1) PT83013B (da)
RU (1) RU2051918C1 (da)
TN (1) TNSN86111A1 (da)
WO (1) WO1987000523A2 (da)
ZA (1) ZA865374B (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
US5338741A (en) * 1986-10-27 1994-08-16 Nestec S.A. 1-hydroxyalkylxanthines and medicaments containing them
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
DD298051A5 (de) * 1989-08-16 1992-02-06 ��@���������@�������k�� Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
DE3942872A1 (de) * 1989-12-23 1991-06-27 Hoechst Ag Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen
IT1240843B (it) * 1990-05-24 1993-12-17 Malesci Istituto Farmacobiologico Derivati xantinici 1-7 sostituiti ad attivita' antiasmatica, loro sali fisiologicamente accettabili, loro composizioni farmaceutiche e procedimento per la loro preparazione.
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5039666A (en) * 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside
EP0484785B1 (en) * 1990-11-07 1996-05-22 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
TW209834B (da) * 1991-12-11 1993-07-21 Hoechst Ag
ATE146078T1 (de) * 1992-02-22 1996-12-15 Hoechst Ag Verwendung von xanthinderivaten zur behandlung von muskelschädigungen nach vollständiger unterbrechung der blutzirkulation
PT584347E (pt) * 1992-03-04 2003-06-30 Cell Therapeutics Inc Compostos de xantina hidroxilados enantiomericos
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US5866576A (en) * 1992-12-16 1999-02-02 Cell Therapeutics, Inc. Epoxide-containing compounds
WO1994015605A1 (en) * 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
AU6092794A (en) * 1993-01-19 1994-08-15 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US5837703A (en) * 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US6020337A (en) * 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
CA2192470A1 (en) * 1994-01-14 1995-07-20 Paul A. Brown Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
WO1995022546A1 (en) * 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
US5965555A (en) * 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
DE10042152A1 (de) * 2000-08-26 2002-03-28 Basf Coatings Ag Mit aktinischer Strahlung aktivierbares Thixotropierungsmittel, Verfahren zu seiner Herstellung und seine Verwendung
DE10122390A1 (de) * 2001-05-09 2002-11-28 Basf Coatings Ag Carbamat-und/oder Allophanatgruppen enthaltende, thermisch härtbare, thixotrope Gemische
DE10139262C1 (de) * 2001-08-09 2003-01-02 Basf Coatings Ag Rheologiehilfsmittel, Verfahren zu seiner Herstellung und seine Verwendung
AU2002304685A1 (en) * 2002-04-24 2003-11-10 Basf Coatings Ag Thermally curable, thixotropic mixtures containing carbamate and/or allophanate groups
KR100872788B1 (ko) * 2002-05-28 2008-12-09 엘지전자 주식회사 드럼세탁기
US8686090B2 (en) * 2003-12-10 2014-04-01 Basf Coatings Gmbh Use of urea crystals for non-polymeric coatings
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
US20090239886A1 (en) * 2008-02-29 2009-09-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8546572B2 (en) * 2008-03-31 2013-10-01 Sun Pharmaceutical Industries Limited Process for the preparation of morphinane analogues
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
WO2011028835A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US9260432B2 (en) 2009-09-02 2016-02-16 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2012031073A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
CN104364255A (zh) 2012-04-13 2015-02-18 康塞特医药品有限公司 取代的黄嘌呤衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
FR1211333A (fr) * 1955-10-19 1960-03-15 Boehringer Sohn Ingelheim Perfectionnements apportés aux procédés pour fabriquer des oxyalcoylxanthines
DE2335170C2 (de) * 1973-07-11 1989-07-20 Hoechst Ag, 6230 Frankfurt 1,3-Dialkyl-7-(hydroxyalkyl)-xanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4576947A (en) * 1967-12-16 1986-03-18 Hoechst Aktiengesellschaft Pharmaceutical compositions
BE795345A (fr) * 1972-02-19 1973-08-13 Albert Ag Chem Werke MEDICAMENT UTILE NOTAMMENT POUR L'IRRIGATION CEREBRALE, PROCEDE DE PREPARATION DE SES MATIERES ACTIVES ET CES MATIERES ElLES-MEMES
CH622519A5 (en) * 1974-07-05 1981-04-15 Hoechst Ag Process for the preparation of hydroxyalkylxanthines
DE2432702C2 (de) * 1974-07-08 1983-01-20 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von Hydroxyalkylxanthinen
CA1075690A (en) * 1974-12-13 1980-04-15 Hoechst Aktiengesellschaft Xanthine derivatives
DE3062499D1 (en) * 1979-04-05 1983-05-05 Beecham Wuelfing Gmbh & Co Kg Dialkoxy- and dioxacycloalkyl-alkyltheobromines, pharmaceutical compositions containing them and their preparation
JPS5838284A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd １−（５′−オキソヘキシル）−３，７−ジメチルキサンチンの製造方法
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
US4575795A (en) * 1983-04-01 1986-03-11 Honeywell Information Systems Inc. Apparatus for detecting a predetermined character of a data string

Also Published As

Publication number Publication date
ES2001019A6 (es) 1988-04-16
IL79457A0 (en) 1986-10-31
BG60767B2 (bg) 1996-02-29
EP0268585A1 (de) 1988-06-01
OA08707A (en) 1989-03-31
PT83013B (pt) 1989-01-30
CN1026112C (zh) 1994-10-05
LT3869B (en) 1996-04-25
US4833146A (en) 1989-05-23
CN86105835A (zh) 1987-01-14
PT83013A (de) 1986-08-01
ZA865374B (en) 1987-02-25
FI89921C (fi) 1993-12-10
IE861917L (en) 1987-01-19
CA1262248A (en) 1989-10-10
CS545386A2 (en) 1990-04-11
NO165803C (no) 1991-04-10
WO1987000523A3 (fr) 1987-02-26
LV5703A3 (lv) 1995-02-20
EP0268585B1 (de) 1990-05-30
AU6143986A (en) 1987-02-10
AR244689A1 (es) 1993-11-30
WO1987000523A2 (en) 1987-01-29
DK139287D0 (da) 1987-03-18
NO871111L (no) 1987-03-18
GR861866B (en) 1986-11-17
DK139287A (da) 1987-03-18
HU198486B (en) 1989-10-30
AU588350B2 (en) 1989-09-14
JPS63501149A (ja) 1988-04-28
KR950001019B1 (ko) 1995-02-07
TNSN86111A1 (fr) 1990-01-01
LTIP1467A (en) 1995-05-25
DE3671627D1 (de) 1990-07-05
NO871111D0 (no) 1987-03-18
RU2051918C1 (ru) 1996-01-10
NO165803B (no) 1991-01-02
IE59025B1 (en) 1993-12-15
MA20739A1 (fr) 1987-04-01
DD261156A5 (de) 1988-10-19
FI880174A (fi) 1988-01-15
FI880174A0 (fi) 1988-01-15
DK157867B (da) 1990-02-26
JPH0788382B2 (ja) 1995-09-27
DE3525801A1 (de) 1987-01-22
DK157867C (da) 1990-07-30
HUT47274A (en) 1989-02-28
NZ216888A (en) 1989-05-29
FI89921B (fi) 1993-08-31
MX9254A (es) 1993-06-01
ATE53211T1 (de) 1990-06-15
KR870700623A (ko) 1987-12-30
PH26262A (en) 1992-04-01

Similar Documents

Publication Publication Date Title
CS272766B2 (en) Method of tertiary hydroxyalkylxanthine production
EP0203721B1 (en) 8-phenyl xanthines
US4289776A (en) Xanthine derivatives
CZ174297A3 (en) Xanthine derivatives, process of their preparation and medicaments containing thereof
EP0357788B1 (en) Pyridazinone derivatives
JPH0130834B2 (da)
US20120035192A1 (en) Selective antagonists of a2a adenosine receptors
US20090163491A1 (en) Substituted 8-[6-amino-3pyridyl]xanthines
US8349848B2 (en) Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors
CS196357B2 (en) Process for preparing new basic substituted derivatives of xanthine
KR100477177B1 (ko) 크산틴화합물,이의제조방법및이를포함하는쇼크상태의치료및예방용약제학적조성물
US20230144283A1 (en) 8-substituted diaryl xanthines as dual a2a-a2b antagonists
US5017577A (en) Methods for treating viral infection
CS272799B2 (en) Method of teriary hydroxylxanthine production
RU2159617C2 (ru) Производные ксантина, их стереоизомеры и физиологически переносимые соли, фармацевтическая композиция, обладающая уменьшающей патологическую гиперактивность эозинофильных гранулятов активностью
JPS6141915B2 (da)
US8569489B2 (en) 7-[4-(Benzhydrylpiperazinyl-1)butyl]-3-methylxanthine and its salts with organic or inorganic acids possessing antihistaminic and antiallergenic activity
RU2333212C1 (ru) ПРОИЗВОДНЫЕ 1-И 7-[ω-(БЕНЗГИДРИЛ-4-ПИПЕРАЗИНИЛ-1)АЛКИЛ]-3-АЛКИЛКСАНТИНОВ, ОБЛАДАЮЩИЕ ПРОТИВОГИСТАМИННОЙ И АНТИАЛЛЕРГИЧЕСКОЙ АКТИВНОСТЬЮ